Dr. Pedro C Barata, MD, MSc - Tulane University - Assistant Professor

Dr. Pedro C Barata

MD, MSc

Tulane University

Assistant Professor

New Orleans, Louisiana | United States

Main Specialties: Oncology

Additional Specialties: Medical Oncology

ORCID logohttps://orcid.org/0000-0002-8890-2951


Top Author

Dr. Pedro C Barata, MD, MSc - Tulane University - Assistant Professor

Dr. Pedro C Barata

MD, MSc

Introduction

Dr. Pedro Barata earned his medical degree from the New University of Lisbon in 2009 and completed his Medical Oncology fellowship in 2016. During his training, he spent one year in the USA rotating at the phase I Department at the M.D. Anderson Cancer Center, Houston and at the Hematology/Oncology Departments, Genitourinary Tumors Group at Taussig Cancer Center, Cleveland Clinic, Cleveland. During his oncology training, he also completed his formal educational program in symptom management in cancer and earned his master’s degree in 2016. After completion of his medical oncology fellowship, he was invited to join the genitourinary group at Taussig Cancer Center where he worked for two years as clinical experimental therapeutics fellow. As a result of his clinical and research work, Dr. Barata authored and co-authored more than 25 research publications in high-quality journals, such as Cancer, Annals of Oncology, British Journal of Cancer, among others. In addition, he presented more than 20 research abstracts presented at important national and international meetings, as well as textbook chapters and clinical reviews. He also served as a reviewer for prestigious peer-reviewed journals such as JAMA Oncology, ASCO, Journal Global Oncology, among many others.
Dr. Barata moved to Tulane University to continue his clinical and research work in the GU field and help to expand the program offered at Tulane Cancer Center.

Primary Affiliation: Tulane University - New Orleans, Louisiana , United States

Specialties:

Additional Specialties:

Research Interests:


View Dr. Pedro C Barata’s Resume / CV

Education

Jan 2016
Universidade de Lisboa Faculdade de Medicina
MSc Palliative Care
Bioethical Department
Sep 2003 - Jul 2009
Universidade Nova de Lisboa
MD
Medicine

Experience

Jul 2016 - Jun 2018
Cleveland Clinic Foundation
Experimental Therapeutics Fellow
Solid Tumors Department
Jan 2011 - Jun 2016
Centro Hospitalar de Lisboa Central
Fellow
Medical Oncology
Aug 2018
Tulane University School of Medicine
Assistant Professor
Hematology and Medical Oncology

Publications

26Publications

596Reads

742Profile Views

31PubMed Central Citations

Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or….

Cancer 2019 Jun 1;125(11):1777-1788. Epub 2019 Apr 1.

Tulane Cancer Center, Tulane University, New Orleans, Louisiana.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32039DOI Listing
June 2019
4 Reads
4.889 Impact Factor

Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.

Invest New Drugs 2019 Apr 7;37(2):331-337. Epub 2018 Nov 7.

Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave/CA60, Cleveland, OH, 44195, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-018-0687-5
Publisher Site
http://dx.doi.org/10.1007/s10637-018-0687-5DOI Listing
April 2019
21 Reads
2.920 Impact Factor

Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.

Clin Genitourin Cancer 2018 12 17;16(6):429-436. Epub 2018 Aug 17.

Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.08.002DOI Listing
December 2018
11 Reads
1.693 Impact Factor

Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study.

Invest New Drugs 2018 12 6;36(6):1085-1092. Epub 2018 Sep 6.

Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave/CA60, Cleveland, OH, 44195, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-018-0660-3
Publisher Site
http://dx.doi.org/10.1007/s10637-018-0660-3DOI Listing
December 2018
36 Reads
2.920 Impact Factor

Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma.

Clin Genitourin Cancer 2018 10 17;16(5):413-419.e1. Epub 2018 Aug 17.

Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.07.018DOI Listing
October 2018
27 Reads
1.693 Impact Factor

Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.

Clin Genitourin Cancer 2018 08 22;16(4):e879-e892. Epub 2018 Feb 22.

Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.02.002DOI Listing
August 2018
27 Reads
1.693 Impact Factor

A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).

Invest New Drugs 2018 06 23;36(3):451-457. Epub 2018 Feb 23.

Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave/CA60, Cleveland, OH, 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0574-0DOI Listing
June 2018
76 Reads
2.920 Impact Factor

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

J Immunother Cancer 2018 Jan 29;6(1). Epub 2018 Jan 29.

Department of Hematology & Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Ave, Desk CA60, Cleveland, OH, 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0319-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789686PMC
January 2018
18 Reads
1 Citation

Treatment of renal cell carcinoma: Current status and future directions.

CA Cancer J Clin 2017 Nov 29;67(6):507-524. Epub 2017 Sep 29.

Professor of Medicine, Cleveland Clinic Lerner College of Medicine; and Leader, Genitourinary Program, Glickman Urological and Kidney Institute, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.3322/caac.21411
Publisher Site
http://dx.doi.org/10.3322/caac.21411DOI Listing
November 2017
62 Reads
6 Citations
100.000 Impact Factor

Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.

Ann Oncol 2017 Oct;28(10):2458-2463

Department of Hematology & Medical Oncology, Taussig Cancer Institute.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdx405DOI Listing
October 2017
13 Reads
1 Citation
7.040 Impact Factor

Outcomes and satisfaction of two optional cadaveric dissection courses: A 3-year prospective study.

Anat Sci Educ 2017 Mar 2;10(2):127-136. Epub 2016 Aug 2.

Department of Anatomy, Nova Medical School, Faculty of Medical Sciences, Universidade Nova De Lisboa, Lisbon, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ase.1638DOI Listing
March 2017
16 Reads
1 Citation

[Pain Intensity and Time to Death of Cancer Patients Referred to Palliative Care].

Acta Med Port 2016 Nov 30;29(11):694-701. Epub 2016 Nov 30.

Cuidados Paliativos. Institutos de Investigação de Bruyere e Ottawa. Universidade de Ottawa. Ottawa. Canadá.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20344/amp.7557DOI Listing
November 2016
10 Reads

RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.

Cancer Treat Rev 2016 Nov 28;50:35-47. Epub 2016 Aug 28.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.08.004DOI Listing
November 2016
15 Reads
17 Citations
7.590 Impact Factor

Symptom clusters and survival in Portuguese patients with advanced cancer.

Cancer Med 2016 10 13;5(10):2731-2739. Epub 2016 Sep 13.

Bruyere Continuing Care, Division of Palliative Care, Department of Medicine, Bruyere and Ottawa Hospital Research Institutes, University of Ottawa, Ottawa, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.860DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083726PMC
October 2016
14 Reads
1 Citation

Bilateral panuveitis associated with Whipple disease - case report.

GMS Ophthalmol Cases 2014 8;4:Doc01. Epub 2014 Jan 8.

Internal Medicine Department, Centro Hospitalar de Lisboa Central EPE, Lisbon, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3205/oc000014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015619PMC
September 2016
11 Reads

Right cardiac intracavitary metastases from a primary intracranial myxofibrosarcoma.

BMJ Case Rep 2016 Mar 24;2016. Epub 2016 Mar 24.

Pathology Department, Centro Hospitalar de Lisboa Central, Lisbon, Portugal Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Lisbon, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2015-214052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823536PMC
March 2016
15 Reads

Corticosteroid sensitivity in gliomatosis cerebri delays diagnosis.

Pract Neurol 2015 Aug 28;15(4):309-11. Epub 2015 Apr 28.

Department of Neuro-Oncology, The University of Texas-M.D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/practneurol-2015-001125DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504780PMC
August 2015
13 Reads

A case of post-radiotherapy gastritis: radiation does not explain everything.

Case Rep Oncol 2015 Jan-Apr;8(1):9-14. Epub 2015 Jan 14.

Department of Pathology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000371653DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327546PMC
March 2015
11 Reads

Breast cancer presents with a paraneoplastic neurologic syndrome.

Case Rep Oncol 2012 Sep 20;5(3):616-21. Epub 2012 Sep 20.

Oncology Department, Centro Hospitalar Lisboa Central, Lisboa, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000345692DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531935PMC
September 2012
14 Reads
2 Citations

Top co-authors

Jorge A Garcia
Jorge A Garcia

Cleveland Clinic Taussig Cancer Institute

12
Petros Grivas
Petros Grivas

University of Patras

9
Brian I Rini
Brian I Rini

Cleveland Clinic Taussig Cancer Institute

8
Prateek Mendiratta
Prateek Mendiratta

Duke University

6
Moshe C Ornstein
Moshe C Ornstein

Cleveland Clinic Taussig Cancer Institute

4
Timothy Gilligan
Timothy Gilligan

Cleveland Clinic

4
Allison Tyler
Allison Tyler

Cleveland Clinic Taussig Cancer Institute

4
Robert Dreicer
Robert Dreicer

Taussig Cancer Institute

3
Moshe Ornstein
Moshe Ornstein

Cleveland Clinic Taussig Cancer Institute

3
Vadim S Koshkin
Vadim S Koshkin

Cleveland Clinic

3